期刊文献+

MicroRNAs与实体肿瘤化疗耐药 被引量:2

MicroRNAs and solid tumors drug resistance
原文传递
导出
摘要 化疗耐药是恶性肿瘤患者成功治疗的主要障碍,多种机制参与肿瘤耐药形成。近来研究表明,microRNAs与肿瘤耐药存在相关性,多种实体肿瘤耐药细胞或组织中microRNAs表达异常,修复异常表达的microRNAs可以改善肿瘤细胞的化疗敏感性。通过对耐药细胞或组织microRNAs表达谱进行研究,有利于耐药机制的深入研究,也有利于发现新的分子靶标以筛查化疗敏感患者。 Drug resistance is major obstacles in the successful treatment of malignant solid tumors. Multiple mechanisms involeve in development of cancer drug resistance. Recent research suggests dysregulation of microRNAs is associated with cancer drug resistance. The profiles of microRNAs in drug resistance cancer cells or tissues are different with sensitivity cells or tissues in various solid tumors. Restoring microRNAs could improve (;hemosensitivity of cancer cells. MicroRNAs expression profiles may provide a critical link for understanding mechanisms involved in ehemoresistance. We can also find a specific nlarker for screening chemosensitivity patients through identification of the mieroRNAs patterns of drug resistance cells or tissues.
出处 《国际外科学杂志》 2011年第3期182-185,共4页 International Journal of Surgery
基金 高等学校博士学科点专项科研基金资助课题(No.20101106110044) 北京市自然科学基金重大项目(No.7100003)
关键词 实体肿瘤 MICRORNAS 化疗药物 耐药 Solid tumors microRNAs Chemotherapeutic agent Drug resistance
  • 相关文献

参考文献1

二级参考文献30

  • 1Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T, et al, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer, Gastroenterology 2007; 133: 647-58,.
  • 2Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69: 7165-9.
  • 3Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
  • 4Shiota M, Izumi H, Tanimoto A, Takahashi M, Miyamoto N, Kashiwagi E, et al. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res 2009; 69: 3148-56.
  • 5Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009; 37: 918-25.
  • 6Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007; 282: 14328- 36.
  • 7Sayed D, Rane S, Lypowy J, He M, Chen IY, Vashistha H, et al. MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol Biol Cell 2008; 19: 3272-82.
  • 8Hilliard A, Hilliard B, Zheng S J, Sun H, Miwa T, Song W, et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006; 177: 8095-102.
  • 9Jansen AP, Camalier CE, Colburn NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005; 65: 6034-41.
  • 10Yang HS, Matthews CP, Clair T, Wang Q, Baker AR, Li CC, et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon . carcinoma cell invasion. Mol Cell Biol 2006; 26: 1297-306.

共引文献21

同被引文献15

  • 1盖晓东,李国利,黄京子,徐鸿洁,王丹.野生型p53基因对肝癌细胞多药耐药的逆转作用及其相关机制[J].癌症,2006,25(8):954-959. 被引量:21
  • 2Gold MA, Tian C, Whitney CW, et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study. Cancer, 2008,112 (9) : 1954- 1963.
  • 3S ve P, Dumontet C. Class In beta tubulin expression in nonsmall cell lung cancer. Rev Mal Respir, 2010, 27(4) : 383-386.
  • 4Izutsu N, Maesawa C, Shibazaki M, et al. Epigenetic modification is involved in aberrant expression of class llI beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol, 2008,32(6) : 1227-1235.
  • 5Loizzi V, Cormio G, Vicino M, et al. Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer. Gynecol Obstet Invest, 2008,65(2) :96-103.
  • 6Lee JM, Lee KB, Nam JH, et al. Prognostic factors in FIGO stage I B- II A small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncal, 2008,19(2) : 321-326.
  • 7S ve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol, 2008,9 (2):168-175.
  • 8杨俊泉,高献书,刘宏侠,韩春.Ⅳ期非小细胞肺癌组织β_Ⅲ-tubulin表达与紫杉类化疗耐药相关[J].第四军医大学学报,2008,29(10):930-932. 被引量:14
  • 9陈文兵,吕卫国,谢幸,程晓东,郑小冬,苏雪锋.局部晚期宫颈癌细胞中XPC、ERCC1的表达与新辅助化疗疗效的关系[J].温州医学院学报,2008,38(3):248-252. 被引量:2
  • 10王雪卿,尹婕,毛宁,张毅,刘兵.细胞周期同步化逆转卵巢癌对紫杉醇耐药的研究[J].现代妇产科进展,2009,18(2):109-112. 被引量:5

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部